Yejin Kim

Dr. Yejin Kim

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YKYejin Kim
Yejin Kim
KBKil Seong Bae
Kil Seong Bae
UCUi Yoon Choi
Ui Yoon Choi
SHSeung Beom Han
Seung Beom Han
JKJong-Hyun Kim
Jong-Hyun Kim
Kim Y, et al. J Korean Med Sci. 2024 Feb;39:e64. https://doi.org/10.3346/jkms.2024.39.e64

24 July 2026 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
SHSeung Beom Han
Seung Beom Han
YKYejin Kim
Yejin Kim
YKYeji Kim
Yeji Kim
JSJin Soon Suh
Jin Soon Suh
JKJong-Hyun Kim
Jong-Hyun Kim

29 October 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
JLJin Lee
Jin Lee
YKYejin Kim
Yejin Kim
YKYeJi Kim
YeJi Kim
SHSeung Beom Han
Seung Beom Han
JSJin Soon Suh
Jin Soon Suh
JKJong-Hyun Kim
Jong-Hyun Kim
Although the clinical impact of empirical antibiotic susceptibility on urinary tract infection (UTI) caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PEs) is limited, the role of definitive antibiotics remains unclear. This study evaluated therapeutic outcomes and recurrence in children with febrile UTI caused by ESBL-PE, focusing on pathogen susceptibility to empirical and definitive antibiotics. Medical records of 376 UTI episodes caused by ESBL-PE in children aged <10 years were retrospectively reviewed, and 319 were analyzed. Episodes were classified as empirical-susceptible (n = 144) and empirical-non-susceptible (n = 175) groups, and further categorized into four groups based on definitive antibiotic susceptibility and treatment duration. Clinical outcomes were comparable between empirical-susceptible and empirical-non-susceptible groups. Among the four definitive-therapy groups, early clinical response did not differ significantly; however, UTI recurrence showed an increasing trend from 1.0% in those receiving empirical and definitive antibiotics to which pathogens were susceptible for ≥7 days to 6.3% in those receiving empirical antibiotics to which pathogens were non-susceptible and not receiving antibiotics to which pathogens were susceptible ≥7 days (p = 0.045). Despite favorable early response to empirical non-susceptible antibiotics, switching to susceptible antibiotics and maintaining therapy for ≥7 days is recommended for children with ESBL-PE UTIs.

1 October 2021 in Annals of Child Neurology
Verified
Journal Article
Open access
PDF file
YKYejin Kim
Yejin Kim
IYILHAN YOO
ILHAN YOO